Induction of Innate Immunity Against Herpes Simplex Virus Type 2 Infection Via Local Delivery of Toll-like Receptor Ligands Correlates with Beta Interferon Production

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2006 Sep 29

PMID 17005672

Citations 45

Authors

Navkiran Gill

Philip M Deacon

Brian Lichty

Karen L Mossman

Ali A Ashkar

Affiliations

Soon will be listed here.

Abstract

Toll-like receptors (TLRs) constitute a family of innate receptors that recognize and respond to a wide spectrum of microorganisms, including fungi, bacteria, viruses, and protozoa. Previous studies have demonstrated that ligands for TLR3 and TLR9 induce potent innate antiviral responses against herpes simplex virus type 2 (HSV-2). However, the factor(s) involved in this innate protection is not well-defined. Here we report that production of beta interferon (IFN-beta) but not production of IFN-alpha, IFN-gamma, or tumor necrosis factor alpha (TNF-alpha) strongly correlates with innate protection against HSV-2. Local delivery of poly(I:C) and CpG oligodeoxynucleotides induced significant production of IFN-beta in the genital tract and provided complete protection against intravaginal (IVAG) HSV-2 challenge. There was no detectable IFN-beta in mice treated with ligands for TLR4 or TLR2, and these mice were not protected against subsequent IVAG HSV-2 challenge. There was no correlation between levels of TNF-alpha or IFN-gamma in the genital tract and protection against IVAG HSV-2 challenge following TLR ligand delivery. Both TNF-alpha(-/-) and IFN-gamma(-/-) mice were protected against IVAG HSV-2 challenge following local delivery of poly(I:C). To confirm that type I interferon, particularly IFN-beta, mediates innate protection, mice unresponsive to type I interferons (IFN-alpha/betaR(-/-) mice) and mice lacking IFN regulatory factor-3 (IRF-3(-/-) mice) were treated with poly(I:C) and then challenged with IVAG HSV-2. There was no protection against HSV-2 infection following poly(I:C) treatment of IFN-alpha/betaR(-/-) or IRF-3(-/-) mice. Local delivery of murine recombinant IFN-beta protected C57BL/6 and IRF-3(-/-) mice against IVAG HSV-2 challenge. Results from these in vivo studies clearly suggest a strong correlation between IFN-beta production and innate antiviral immunity against HSV-2.

Citing Articles

Influence of the Composition of Cationic Liposomes on the Performance of Cargo Immunostimulatory RNA.

Bishani A, Makarova D, Shmendel E, Maslov M, Senkova A, Savin I Pharmaceutics. 2023; 15(9).

PMID: 37765155 PMC: 10535620. DOI: 10.3390/pharmaceutics15092184.

Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+CD44+ CD62L-CD8+ T Cells and Memory CCR10+B220+CD27+ B Cells into the Infected Vaginal Mucosa.

Dhanushkodi N, Prakash S, Quadiri A, Zayou L, Srivastava R, Tran J J Immunol. 2023; 211(1):118-129.

PMID: 37222480 PMC: 10330291. DOI: 10.4049/jimmunol.2300093.

Does IFITM3 link inflammation to tumorigenesis?.

Lee J BMB Rep. 2022; 55(12):602-608.

PMID: 36404597 PMC: 9813432.

Type I interferon regulates proteolysis by macrophages to prevent immunopathology following viral infection.

Lee A, Feng E, Chew M, Balint E, Poznanski S, Giles E PLoS Pathog. 2022; 18(5):e1010471.

PMID: 35512020 PMC: 9113601. DOI: 10.1371/journal.ppat.1010471.

Immunoregulatory Functions of Interferons During Genital HSV-2 Infection.

Feng E, Balint E, Vahedi F, Ashkar A Front Immunol. 2021; 12:724618.

PMID: 34484233 PMC: 8416247. DOI: 10.3389/fimmu.2021.724618.

References

Gillgrass A, Ashkar A, Rosenthal K, Kaushic C . Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J Virol. 2003; 77(18):9845-51. PMC: 224606. DOI: 10.1128/jvi.77.18.9845-9851.2003. View

Ashkar A, Bauer S, Mitchell W, Vieira J, Rosenthal K . Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol. 2003; 77(16):8948-56. PMC: 167233. DOI: 10.1128/jvi.77.16.8948-8956.2003. View

Beutler B, Hoebe K, Du X, Ulevitch R . How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol. 2003; 74(4):479-85. DOI: 10.1189/jlb.0203082. View

Sajic D, Ashkar A, Patrick A, McCluskie M, Davis H, Levine K . Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol. 2003; 71(4):561-8. DOI: 10.1002/jmv.10518. View

Janssens S, Beyaert R . Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev. 2003; 16(4):637-46. PMC: 207104. DOI: 10.1128/CMR.16.4.637-646.2003. View

Zhang D, Zhang G, Hayden M, Greenblatt M, Bussey C, Flavell R . A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 2004; 303(5663):1522-6. DOI: 10.1126/science.1094351. View

Liu G, Zhai Q, Schaffner D, Bradburne C, Wu A, Hayford A . IL-15 induces IFN-beta and iNOS gene expression, and antiviral activity of murine macrophage RAW 264.7 cells. Immunol Lett. 2004; 91(2-3):171-8. DOI: 10.1016/j.imlet.2003.11.015. View

Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M . The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004; 5(7):730-7. DOI: 10.1038/ni1087. View

Akira S, Takeda K . Toll-like receptor signalling. Nat Rev Immunol. 2004; 4(7):499-511. DOI: 10.1038/nri1391. View

10.

Ulevitch R . Therapeutics targeting the innate immune system. Nat Rev Immunol. 2004; 4(7):512-20. DOI: 10.1038/nri1396. View

11.

Kawai T, Sato S, Ishii K, Coban C, Hemmi H, Yamamoto M . Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol. 2004; 5(10):1061-8. DOI: 10.1038/ni1118. View

12.

Ashkar A, Yao X, Gill N, Sajic D, Patrick A, Rosenthal K . Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis. 2004; 190(10):1841-9. DOI: 10.1086/425079. View

13.

McDermott M, SMILEY J, Leslie P, Brais J, Rudzroga H, Bienenstock J . Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol. 1984; 51(3):747-53. PMC: 255840. DOI: 10.1128/JVI.51.3.747-753.1984. View

14.

Pennanen N, Lapinjoki S, Palander A, Urtti A, Monkkonen J . Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion. Int J Immunopharmacol. 1995; 17(6):475-80. DOI: 10.1016/0192-0561(95)00030-6. View

15.

Stark G, Kerr I, Williams B, Silverman R, Schreiber R . How cells respond to interferons. Annu Rev Biochem. 1998; 67:227-64. DOI: 10.1146/annurev.biochem.67.1.227. View

16.

Milligan G . Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. J Virol. 1999; 73(8):6380-6. PMC: 112717. DOI: 10.1128/JVI.73.8.6380-6386.1999. View

17.

Schaefer T, Fahey J, Wright J, Wira C . Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C). J Immunol. 2005; 174(2):992-1002. DOI: 10.4049/jimmunol.174.2.992. View

18.

Gillgrass A, Tang V, Towarnicki K, Rosenthal K, Kaushic C . Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. J Virol. 2005; 79(5):3117-26. PMC: 548483. DOI: 10.1128/JVI.79.5.3117-3126.2005. View

19.

Gill N, Rosenthal K, Ashkar A . NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection. J Virol. 2005; 79(7):4470-8. PMC: 1061577. DOI: 10.1128/JVI.79.7.4470-4478.2005. View

20.

Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T . IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005; 434(7034):772-7. DOI: 10.1038/nature03464. View